Disease · MONDO_0002177

hyperinsulinism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperinsulinism. Diseases, record MONDO_0002177. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002177

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperinsulinism; Open Targets
Open Targets ID: MONDO_0002177; Open Targets
Other names: Elevated insulin level, Hyperinsulinemia, hyperinsulinism (disease); Open Targets
Disease Ontology: DOID:2018; Disease Ontology
MeSH: D006946; MeSH
Highest stage of its drugs: Approval, for 1 of its 7 drugs, from DailyMed; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DIAZOXIDE	CHEMBL181	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
MECASERMIN	CHEMBL1201716	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ROSIGLITAZONE	CHEMBL121	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DASIGLUCAGON	CHEMBL4297741		Phase 2	TTD	1	0	0	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets62

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
GCGR	Glucagon receptor	1	Glucagon receptor agonist	Phase 2	https://conductscience.org/library/genes/2642	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor agonist	Phase 2	https://conductscience.org/library/genes/3480	Drugs and targets
KCNJ11	ATP-sensitive inward rectifier potassium channel 11	1	Potassium channel, inwardly rectifying, subfamily J, member 11 opener	Approval	https://conductscience.org/library/genes/3767	Drugs and targets
KCNJ8	ATP-sensitive inward rectifier potassium channel 8	1	Potassium channel, inwardly rectifying, subfamily J, member 8 opener	Approval	https://conductscience.org/library/genes/3764	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4537	Drugs and targets

1 to 10 of 62

See all 62 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00618072	EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance	Phase 2	46	2014-03-28	Hyperinsulinemia, Insulin Resistance, Obesity	METFORMIN, ROSIGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT00015691	Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities	Not applicable	105		HIV Infections, Lipodystrophy, Hyperinsulinemia	METFORMIN, ROSIGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT00306683	Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions	Phase 3	40		Hypothalamic-pituitary Lesions, Craniopharyngiomas	DIAZOXIDE	Its record names the disease	ClinicalTrials.gov
NCT05989347	Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy	Phase 1	20		Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer	DAPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT00004700	Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	Phase 2	16		Hyperinsulinism	MECASERMIN	Its record names the disease	ClinicalTrials.gov
NCT00004825	Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	Not applicable	10		Hyperinsulinism	MECASERMIN	Its record names the disease	ClinicalTrials.gov
NCT00987168	Sandostatine® LP and Hyperinsulinism	Phase 2	10		Congenital Hyperinsulinism	OCTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT06606327	Diazoxide Suppression Test P&F Study	Phase 1	1		Insulin Resistance, Hyperinsulinemia, Obesity	DIAZOXIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27603903	DERIVED	1	PubMed
26789348	DERIVED	1	PubMed
25259787	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002177

GET https://conductscience.org/api/diseases/v1/MONDO_0002177/targets?page=2

API reference For AI assistants